Combination product: Trastuzumab + Pertuzumab

DRUG3 trials

Sponsors

Seagen, a wholly owned subsidiary of Pfizer, Peking University Cancer Hospital & Institute

Conditions

Breast CancerHER2 Positive Breast CancerHER2-positive Breast Cancer

Phase 2

Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

Not yet recruitingNCT07527806

Peking University Cancer Hospital & InstituteBreast Cancer

Start: 2026-05-01End: 2029-12-31Target: 156Updated: 2026-04-17

Phase 3

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Active, not recruitingNCT05132582

Seagen, a wholly owned subsidiary of PfizerHER2 Positive Breast Cancer

Start: 2022-03-07End: 2027-09-28Updated: 2026-04-20

Unknown Phase

Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer

Not yet recruitingNCT07470203

Peking University Cancer Hospital & InstituteHER2-positive Breast Cancer

Start: 2026-03-31End: 2029-09-30Target: 42Updated: 2026-03-13

Related Papers

Abstract GS1-01: Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer

Clinical Cancer Research2026-02-17

HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

2025-12-10

Pyrotinib and Nab‐Paclitaxel in <scp>HER2</scp>‐Positive Breast Cancer (<scp>PANHER</scp> Trial): A Prospective, Single‐Arm, Phase <scp>II</scp> Trial

Cancer Science2025-04-22

heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer

BMC Cancer2024-05-246 citations

Abstract PO1-19-11: Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for HER2+ Metastatic Breast Cancer (HER2CLIMB-05, Trial in Progress)

Cancer Research2024-05-02

Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial

Nature Communications2023-12-1419 citations

HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer.

Journal of Clinical Oncology2023-06-016 citations

Abstract CT065: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)

Cancer Research2023-04-14

Abstract OT2-16-03: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)

Cancer Research2023-03-011 citations

Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress).

Journal of Clinical Oncology2022-06-012 citations